Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: Gilead is an independent biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for life-threatening infectious diseases, including HIV, fungal infections, and hepatitis B. The company markets five products: Viread (HIV), AmBisome (fungal infections), Tamiflu (influenza, marketed by partner Hoffmann-La Roche), Vistide (CMV retinitis), and DaunoXome (Kaposi's sarcoma).
Strategic Shift: In December 2001, Gilead completed the sale of its oncology assets and Boulder, Colorado operations to OSI Pharmaceuticals, Inc., for approximately $168.8 million in cash and stock, to refocus on its core infectious disease expertise.
Key Financial Metrics
| Metric | 2001 | 2000 | Change |
|---|---|---|---|
| Total Revenues | $233.8 million | $195.6 million | +19.5% |
| Net Product Sales | $191.0 million | $149.7 million | +27.6% |
| Operating Loss | $(120.7) million | $(52.3) million | Widened |
| Net Income (Loss) | $52.3 million | $(56.8) million | Turnaround to Profit |
| EPS (Diluted) | $0.26 | $(0.31) | N/A |
| Cash & Equivalents | $582.9 million | $512.9 million | +13.6% |
| Long-Term Debt | $250.0 million | $250.0 million | Flat |
| Working Capital | $627.6 million | $535.6 million | +17.2% |
Note: Net income for 2001 includes a non-operating gain of $157.8 million from the sale of oncology assets and an $8.8 million gain from the sale of an unconsolidated affiliate. Excluding these items, the company reported an operating loss.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 19.5% to $233.8 million, driven primarily by a 17% increase in AmBisome sales ($164.5 million) and the initial commercial launch of Viread ($15.6 million in 2001, compared to zero in 2000).
- Expense Increases: Research and Development (R&D) expenses rose 40% to $185.6 million, largely due to Phase III trials for Viread and adefovir dipivoxil (Hepatitis B), and upfront payments for the Cidecin license. Selling, General, and Administrative (SG&A) expenses increased 52% to $125.1 million to support the global launch of Viread.
- Asset Sale: The divestiture of oncology assets resulted in a significant non-operating gain, transforming a net loss in 2000 into a net profit in 2001.
- Foreign Currency Impact: A stronger U.S. dollar negatively impacted reported revenues from European sales, though underlying sales volume for AmBisome grew approximately 20% excluding currency effects.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Product Pipeline: Gilead expects Viread sales to increase significantly in 2002, becoming a larger percentage of total revenues. The company has filed for regulatory approval of adefovir dipivoxil for Hepatitis B in the U.S. and Europe based on positive Phase III data.
- Expense Guidance: Management expects R&D expenses in 2002 to decrease to $140–$150 million (15–25% lower than 2001) following the oncology asset sale. SG&A expenses are expected to increase to $180–$190 million to support Viread marketing and the anticipated launch of adefovir dipivoxil.
- Profitability: The company has a history of operating losses and an accumulated deficit of $453.7 million. It does not expect to be profitable on a full-year operating basis in the foreseeable future without significant product sales growth.
Risks and Contingencies
- Market Acceptance: Viread faces substantial competition from 17 other HIV drugs. Success depends on physician adoption and reimbursement, particularly for treatment-naive patients where data is still emerging.
- Competition: AmBisome faces competition from lower-priced conventional amphotericin B and new approvals like caspofungin (Merck) and voriconazole (Pfizer).
- Regulatory Uncertainty: Approval of adefovir dipivoxil for Hepatitis B is not guaranteed. Cidecin failed to meet primary endpoints in a Phase III trial for pneumonia, delaying European regulatory filings.
- Collaboration Dependence: Revenue relies heavily on partners (Roche for Tamiflu, Fujisawa for AmBisome in the U.S.). Production issues with Roche's Tamiflu liquid suspension were noted but deemed immaterial.
- Foreign Exchange: A significant majority of sales are denominated in foreign currencies; a stronger U.S. dollar reduces reported revenue.
Key Facts for Investor Verification
- Revenue Concentration: Verify the sustainability of AmBisome, which accounted for 78% of total revenues in 2001, amidst increasing competition.
- Viread Trajectory: Monitor Q1-Q4 2002 sales data for Viread to confirm if it achieves the projected growth to offset declining AmBisome margins.
- Non-Recurring Gains: Distinguish between the $157.8 million gain from the oncology asset sale and core operating performance when assessing profitability.
- Regulatory Milestones: Track the FDA and EU approval status of adefovir dipivoxil for Hepatitis B, a critical future revenue driver.
- Cash Burn Rate: Assess the $582.9 million cash balance against the projected increase in SG&A expenses and continued R&D spending to determine runway without additional financing.